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Cystic fibrosis is a genetic disorder that impairs mucus clearance in the lungs, 
causing chronic inflammation and recurrent infections. Several airway clearance 
modalities are recommended to improve or preserve lung function, including chest 
percussion and exercise. However, there is no clinical consensus on the best treatment 
regimen to maximize the effect of airway clearance therapies and exercise. The purpose 
of this study is to determine whether a structured order of exercise and airway clearance 
therapy improves lung function. Using a randomized study, we will evaluate the 
effectiveness of a structured regimen compared to a non-structured regimen by following 
lung function over one year. Upon completion, we expect the structured program will 
result in improved lung function when compared to the non-structured program. Our 
results may benefit cystic fibrosis patients by informing the adoption of structured 














Chapter 1 – Introduction  
1.1 Background  
 
Cystic fibrosis (CF) is an autosomal recessive disease that affects 1 in every 3,000 
to 4,000 live births.1 It is estimated that over 30,000 people in the United States have CF. 
The disease is a result of loss of function mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene,2 which causes decreased chloride and bicarbonate 
secretion and impaired fluid transport.3 The most severe clinical impact in terms of 
morbidity and mortality of CF is manifested in the lungs.4 CFTR proteins in the lungs are 
responsible for maintaining airway pH and fluid balance at the mucosal interface, both of 
which ultimately modify the viscosity of mucus.5 Mutations in these proteins cause an 
impairment in mucus clearance and makes the lungs more susceptible to mucoid 
impaction.6 Impaired mucociliary clearance in CF contributes to bacterial pathogen 
colonization and growth that causes recurrent infections and can lead to exacerbations.7  
In addition to impaired mucus clearance, the deficiency in bicarbonate secretion 
causes decreased pH within the lungs.5 This acidic environment inactivates antimicrobial 
peptides in the lungs and results in an impaired host defense. This, in turn, leads to 
“chronic non-resolving inflammation driven by continuous recruitment of immune 
cells.”5 The immune cells recruited into the lungs release oxidants and proteases that 
damage the lung tissue. Ultimately, this excessive inflammatory response leads to the 
development of bronchiectasis and further impairments in mucociliary clearance.  
Overall, impaired mucus clearance in CF leads to chronic inflammation and tissue 
destruction that decreases lung function, increases morbidity, and increases mortality.6 
Progressive respiratory insufficiency is the most common cause of mortality for people 
with CF.8 In fact, 85% of deaths in cystic fibrosis are due to lung disease.9 Clinically, the 
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amount of air expired in the first second of forced expiration, known as FEV1, is used to 
monitor disease severity and progression.10 For example, exacerbations have been shown 
to directly cause a decrease in lung function and an increase in mortality.11 Importantly, 
lower lung function and more frequent exacerbations also negatively impact patients’ 
health-related quality of life.12,13 The detrimental effects of decreased lung function and 
increased exacerbations on patients’ overall health and quality of life underline the 
importance of preserving lung function and preventing exacerbations.  
With the goal to increase mucus clearance, decrease exacerbations, and improve 
lung function,14 patients with CF spend on average 108 minutes performing CF 
treatments daily.15 In addition to medical treatments, therapies include airway clearance 
therapy (ACT) and exercise. ACT can be accomplished through multiple modalities, 
including breathing techniques, percussion, drainage, chest compression, and physical 
activity.9 As studies have shown that ACT increases sputum clearance, maintains lung 
function, and improves quality of life, it is recommended for all patients with CF.9 Also, 
aerobic exercise is recommended as an adjunct to ACT due to its benefit in lung function 
as well as overall physical health.  
An important part of CF treatment is the use of CFTR modulators. These 
medications target specific molecular defects in CFTR proteins and lead to improved or 
restored function.16 CFTR modulators improve lung function, decrease the risk of 
exacerbations, decrease the rate of lung function decline, and improve mucociliary 
clearance.16 Recently available triple combination therapy significantly improved lung 
function with an average increase of 10% in FEV1.
17 These results marked significant 
progress in advancing the treatment options for people with CF.  
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In summary, CF is a multiorgan, hereditary disease that adversely impacts the 
lungs and leads to a decline in lung function over time. It is critical to moderate this 
decline to prevent exacerbations, infections, and respiratory failure. Preservation of lung 
function is also important to maintain a higher quality of life for patients. To accomplish 
this, patients partake in an extensive treatment regimen with the goal of increasing mucus 
clearance, preventing exacerbations, and improving lung function.  
1.2 Statement of the Problem  
 
Lung function decline is a common clinical manifestation of cystic fibrosis that 
often progresses through adulthood. Since patients spend an extensive amount of time on 
treatments to moderate this decline, it would be helpful to ensure that treatments are 
performed beneficially. We hypothesize that integrating ACT and exercise would 
improve lung function and quality of life for CF patients. Exercise and ACT are both 
recommended in the treatment of CF, but there is limited data on a formalized 
combination of the two over an intervention period longer than 2-4 days.18-21  
This study will combine ACT and exercise with the aim of maximizing the 
effectiveness of therapy. Importantly, this study will take place over 1 year, thus allowing 
us to longitudinally follow lung function as well as our secondary outcomes. A key 
strength of this study is that it will help understand whether the integration of ACT and 
exercise plays a significant role in lung function, thus allowing patients to maximize 
results with their treatments. The results of this study could inform future 
recommendations for how to most effectively perform ACT and exercise in CF. 




The primary goal of our study is to assess the effectiveness of a structured ACT 
and exercise program in improving lung function over 1 year. Our secondary goals are to 
evaluate the effect of the structured program on the frequency of exacerbations and self-
reported quality of life. Our primary outcome is change in FEV1 over 1 year. This will be 
measured quarterly, so changes can be trended during the course of the year. Secondary 
outcomes will include number of exacerbations and health-related quality of life. 
Exacerbations will be assessed through a medical record chart review and defined 
according to previously reported criteria. Quality of life will be measured through a 
survey given to patients at each quarterly visit.  
1.4 Hypothesis  
 
A structured program of airway clearance therapy and exercise in adults with 
cystic fibrosis will significantly improve baseline FEV1 percent predicted over one year 
compared to a non-structured program.  
1.5 Definitions  
 
Airway Clearance Therapy (ACT): ACT is a broad term that covers a variety of 
techniques used to clear mucus from the lungs.22 It includes chest physiotherapy, active 
breathing techniques, positive expiratory pressure therapy, vibration, and exercise. This is 
usually started at the time of diagnosis and is performed daily.  
FEV1: FEV1 is the volume of air forcefully exhaled in 1 second.
23 It is measured using 
spirometry and used to determine the presence of airflow obstruction. It is often 
expressed as a percent predicted value to clinically classify the severity of the disease. 
The percent predicted is calculated by comparing to a healthy reference population with 
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Chapter 2 – Review of the Literature  
2.1 Introduction 
 
A review of the literature was performed from December 6, 2019 through June 5, 
2020 using Pubmed, Ovid, Scopus, and Cochrane Medical Library. Full articles were 
used after reading the titles and abstracts to ensure topic relevance. The search terms used 
for the relationships between our independent and dependent variables included Cystic 
Fibrosis, Airway Clearance Therapy, Respiratory Therapy, Physiotherapy, Exercise, 
Exercise Therapy, Physical Activity, Lung Function, FEV1, Sputum Production, Sputum 
Expectoration, Healthy Adults, Exacerbations, Quality of Life, Adherence, and Treatment 
Adherence. Key terms used for information regarding study methodology included Cystic 
Fibrosis, Adherence, Age, Lung Function, Lung Function Decline, CFTR Mutation, 
Bacterial Colonization, Pseudomonas aeruginosa, Burkholderia cepacia, Triple Therapy, 
Spirometry, Spirometry Guidelines, Pulmonary Function Tests, NHANES III, FEV1 
Variability, Quality of Life, Cystic Fibrosis Questionnaire Revised, Diagnostic Criteria, 
Minimal Clinically Important Difference, Exercise, and Adverse Events.  
2.2 Cystic Fibrosis and Airway Clearance Therapy  
 
ACT is used in CF to help facilitate mucus clearance. The physiological 
mechanism is likely a combination of multiple effects.1 One is an increase in absolute 
peak expiratory flow rate that pushes mucus to the oropharynx. Another is a decrease in 
the mucus viscosity as a result of oscillations that leads to increased transport. Lastly, 
ACT increases spontaneous coughs that clear mucus through mechanical stimulation.  
ACT can be delivered using different modalities. Conventional chest 
physiotherapy (CPT) includes postural drainage, percussion, and vibration and has been a 
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part of therapy for over forty years.2 More recently, methods like high-frequency chest 
wall oscillation (HFCWO) and oscillating positive expiratory pressure (OPEP) have been 
introduced with the goal of making ACT easier to adhere to at home. HFCWO works by 
creating cough-like forces and vibrations to loosen mucus in the lungs, and OPEP creates 
positive pressure to keep airways open while creating vibrations to loosen mucus. 
Increasing mucus transport within the lungs is critical to help prevent infections and 
inflammation.3 With multiple options for ACT, there have been numerous studies 
comparing the efficacy of each modality.  
The Cystic Fibrosis Foundation’s (CFF) Pulmonary Therapies Committee 
reviewed studies on ACT by focusing on sputum clearance, lung function, exacerbations, 
and quality of life.4 Evidence set forth by the CFF review determined that ACT has a 
moderate benefit in increased sputum clearance, improved lung function, and better 
quality of life. Therefore, the CFF currently recommends ACT for all patients with CF. 
The CFF committee also determined that although all of these methods are considered to 
be beneficial, there is insufficient data to suggest that one modality of ACT is superior to 
another. Therefore, they recommended that the prescribed form of ACT should be 
individualized to the patient.  
For example, a crossover study evaluated HFCWO and OPEP by randomizing 29 
CF patients to 4 weeks of each therapy separated by a 2-week washout period.2 The 
primary outcome was spirometry and lung volumes, and the secondary outcomes were 
patient satisfaction and compliance. The results showed no significant differences in 
FEV1 between the two therapies. Also, since there was no significant decline in lung 
function from baseline with either therapy, both options were considered effective. In 
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terms of patient opinions, reported efficacy was significantly higher for HFCWO, and 
reported convenience was significantly higher for OPEP. Patient preference was 50% for 
HCFWO, 37% for OPEP, and 13% still preferred CPT. Lastly, patient reported adherence 
rates were similar at 88% for HFCWO and 92% for OPEP.  
These results are consistent with the CFF recommendation that no ACT modality 
is superior in terms of effectiveness. This study also demonstrates the variation in patient 
preferences between HFCWO, OPEP, and CPT. The inclusion of patient preference as an 
outcome is a strength of this study because it demonstrates the importance of allowing 
patients to choose their ACT method. The results of this study and the current 
recommendations both support our reasoning that patients in our study may complete 
their preferred method of ACT without significantly confounding our results.  
Similar results were found in a non-inferiority study that compared multiple forms 
of ACT with FEV1 as the primary outcome.
5 They randomized 75 patients with CF to 
active breathing, autogenic drainage, positive expiratory pressure (PEP), or oscillating 
PEP (OPEP). The frequency and duration of ACT were individualized for the 
participants. Lung function measurements were taken at 0, 6, and 12 months. At the end 
of 1 year, they found no significant difference (P = 0.35) in FEV1 between all 5 
modalities, but they did find a significant decline (P = 0.02) in FEV1 overall. The FEV1 
percent predicted change for the whole group was -1.8%.  
A strength of this study was allowing subjects to complete their individually 
required amount of ACT. The results show that even with varying amounts of ACT, there 
was no significant difference between the groups. They used this design because it is 
more similar to clinical practice since patients have different requirements and 
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preferences for ACT. Since our study timeframe is also 1 year, this approach seems the 
most feasible as patient requirements change over time. As a whole, these results support 
that if the patients in our study complete their preferred form of ACT for an 
individualized amount of time, it should not cause significant differences between 
groups.  
Another important discussion point from this study is the statistically significant 
decline in FEV1 over the year. The decrease of -1.8% of percent predicted FEV1 is 
similar to the international average during the study time at -2.0%. Since this study lasted 
1 year, the results show the progressive decline in lung function in patients with CF 
despite therapies. As our study uses the same time period, we may potentially see a 
decline in lung function in both groups, but we expect a slower decline in the intervention 
group. This will be reflected in our statistical analysis by using the mean absolute change 
in baseline FEV1.  
The studies discussed above support the recommended guidelines that ACT is 
beneficial, and there are no significant differences between ACT modalities. The results 
of these studies also demonstrate the importance of recognizing that CF patients require 
different amounts of ACT, and they have different preferences for ACT modalities.  
2.3 Exercise  
2.3.1 Exercise Benefits in Healthy Adults   
It is well understood that exercise has numerous positive health effects and is 
frequently encouraged for most adults. For example, a crossover study evaluated the 
effect of exercise on lung function.6 They included healthy adults ages 25-55 and 
recruited a total of 24,536 participants. Baseline lung function measures were taken, and 
participants were categorized to an activity level ranging from sedentary to active. They 
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found a significant association between FEV1 and physical activity (measured in miles of 
walking or jogging) with a P value of  < 0.001. The authors concluded that being 
sedentary was associated with lower lung function.  
In addition to pulmonary health, exercise also affects quality of life. For example, 
a study assigned 36 subjects who did not regularly exercise to 20 minutes of aerobic 
exercise 3 times per week in addition to weight training.7 They measured quality of life at 
baseline and every 8 weeks for 24 weeks using the Health Status Survey. They found a 
significant improvement in physical functioning (P = 0.004), bodily pain (P = 0.005), 
general health (P = 0.009), vitality (P < 0.001), and mental health scores (P = 0.005) 
compared to controls. A significant improvement was also seen in depression (P = 0.048) 
and stress (P = 0.036) in the intervention group compared to controls. The studies 
discussed above show the benefit of exercise on both physical and mental health in the 
general population. We will apply these concepts to adults with CF and aim to have 
similar effects with a structured exercise and ACT program.  
2.3.2 Exercise and Cystic Fibrosis  
Similar to the results shown in healthy adults, many studies have shown the 
benefits of exercise for patients with CF. These benefits include improved aerobic 
capacity, quality of life, weight gain, and lung function.8 Multiple proposed mechanisms 
contribute to the benefit of exercise on lung function. This includes mechanical vibrations 
similar to ACT, increased ventilation, and inhibition of the sodium channel in the 
respiratory epithelium that results in increased water content of mucus in the lungs. 9 
These mechanisms ultimately result in increased mucus clearance. Conversely, low 
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physical activity can cause decreased mucus clearance, thus leading to an increased risk 
of infections and ultimately lung function decline.10  
The CFF Pulmonary Therapies Committee reviewed the data on the benefit of 
aerobic exercise in patients with CF.4 They determined that aerobic exercise should be 
recommended to patients as adjunct therapy due to its moderate benefit in airway 
clearance, as well as a reduced risk of cardiovascular disease, osteoporosis, and 
depression. Despite the benefits of exercise mentioned above and to be discussed below, 
disease burden and adherence remain obstacles in implementation.8 Our proposed 
intervention will aim to address both of these issues by creating a structured exercise 
program to mitigate the severity of lung function decline and improve adherence.  
2.3.3 Exercise and Lung Function  
Orenstein et al. conducted a 3-month supervised running program for people with 
CF while measuring exercise tolerance and pulmonary function.11 It included 35 subjects 
who volunteered and were divided into either the exercise or the control group. All 
patients completed an initial evaluation including oxygen consumption and pulmonary 
function tests by exercising on a bicycle. The control group was instructed to maintain 
their usual level of activity, and the exercise group was assigned to three, 1-hour training 
sessions per week. The training consisted of a 5-10 minute warm-up with stretching, 10 
minutes of jog-walk that increased to 30 minutes over the 3 months, a 5-minute cool-
down of slow walking, and lastly recreational games. During the jog-walk, participants 
were to measure their heart rate by pulse palpation and maintain 70-85% of their 
maximum heart rate. The participants repeated the same initial tests at the end of the 3 
months. They found a statistically significant (P < 0.005) improvement in the exercise 
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tolerance of the exercise group, and the exercise tolerance of the control group was 
slightly lower although not statistically significant. The FEV1 of the control group was 
also significantly lower at the end of 3 months compared to baseline. Based on the 
results, they concluded that the majority of patients with CF could benefit from a similar 
exercise program.  
This study helps justify the importance of exercise for patients with CF in 
improving exercise tolerance. Although they were unable to show a significant 
improvement in lung function, they noted no worsening in any lung function 
measurements in the exercise group. The lack of significant data on change in lung 
function may in part reflect the short, 3-month time frame of this study. The rate of lung 
function decline in FEV1 varies greatly, but a separate study found the median decline in 
FEV1  percent predicted to be around 2% per year in middle age.
12 Since this is not a 
dramatically large difference, and half of the people in the study had less than a 2% 
decrease, it is plausible that FEV1 would not vary significantly over 3 months. Our 
proposed intervention will last for 1 year, thus providing more data points over time to 
measure changes in lung function.  
Furthermore, our study’s exercise program will be performed individually instead 
of as a group.  As a result, our findings will be better generalizable to the CF population 
and more easily implemented into each individual’s daily schedule. Lastly, this study did 
not follow the number of exacerbations or quality of life as an outcome. As exacerbations 
are closely connected to lung function, disease progression, and quality of life, our study 
will use these as important secondary outcomes.  
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Another study on exercise and lung function in Swiss CF centers randomized 42 
participants to strength training, aerobic training, or no exercise.9 The intervention groups 
participated in 30-45 minutes of exercise 3 times per week for the first 6 months. For the 
first 6 months, participants received phone calls once a month to discuss adherence. For 
the following 6 months, participants were encouraged to continue with their assigned 
training without phone calls. At 3, 6, 12, and 24 months, participants returned to their 
health centers to measure outcomes including FEV1, body composition, and physical 
activity. To measure compliance, the strength-training group filled out cards at the gym, 
and the aerobic training group wore heart rate monitors. They noted that 80% of all the 
participants performed their 3 days of exercise per week, and all participants completed at 
least 65% of all training sessions. This data shows that participants were generally 
adherent to their assigned exercise program over the 6 months.  
The results of this study showed a significant (P < 0.05) improvement in the FEV1 
of patients in both of the training groups compared to control at 3, 6, and 12 months. 
These differences were noted to range from 8-10% at the 6-month time point. They also 
found a significant (P < 0.05) improvement in hyperinflation and aerobic performance in 
the training groups compared to the control at 6 months. Unlike the Orenstein et al. study, 
this study found a significant change in FEV1 with exercise. The longer study period of a 
total of 12 months, with 6 months of intervention, is likely contributory to this result. Our 
study will have 1 year of intervention with quarterly measurements to ensure adequate 
time to measure changes in lung function. This study used monthly phone calls during the 
first 6 months to encourage adherence to the assigned program, and they noted the 
improved effects they saw at 6 months began to taper down at the end of 1 year. They 
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suggest that for training to be effective, it must be continuously supervised for long-term 
results. Our study will use this recommendation in our design to increase adherence to the 
assigned interventions.  Lastly, similar to the Orenstein et al. study, this study did not 
measure exacerbations or quality of life of the participants.  
2.3.4 Exercise and Sputum Expectoration  
Sputum expectoration is a commonly used outcome in CF. A study by Dwyer et 
al. measured sputum production in patients immediately after exercise on a treadmill and 
a bicycle compared to resting breathing.13 The study was a 3-day crossover design that 
involved fourteen adults with CF in Australia. The participants were assigned to 20 
minutes of resting breathing, cycle exercise, or treadmill exercise, during which 
ventilation and respiratory flow were measured. Ease of expectoration and sputum 
properties were measured before, immediately after, and twenty minutes after resting. 
They found no significant differences in the ease of expectoration when comparing 
before and after both the treadmill and cycle interventions, but they did see a trend (P = 
0.096) in improved ease in the treadmill group compared to control and a significant (P = 
0.034) improvement in ease in the cycling group compared to control. They measured 
ventilation and respiratory flow in terms of minute ventilation, peak inspiratory flow, and 
peak expiratory flow, and all were significantly higher with treadmill exercise and 
cycling compared to controls. Overall, this study showed improved ventilation and thus 
ease of sputum expectoration with exercise compared to the control group.  
This study did not measure our primary outcome of FEV1 and instead focused on 
sputum expectoration as its primary outcome. It can be suggested that increased sputum 
expectoration leads to decreased infections and exacerbations, thus improving or better 
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preserving lung function over time. However, measuring sputum production may not 
correlate as well with clinical outcomes as FEV1. In CF, patients range from low-sputum 
producers to high-sputum producers, thus resulting in a high degree of variability.14 This 
is due to many factors, including the willingness to expectorate, swallowing of sputum, 
and differences in cough that alter the mobilization of sputum. Furthermore, individual 
production varies depending on day and time. For example, production is usually higher 
in the morning. Lastly, it can be difficult to determine if the increase in sputum is due to 
increased production or increased clearance. For these reasons, we will measure lung 
function over time instead of sputum expectoration.   
2.3.5 Exercise and Quality of Life  
In addition to lung function and sputum expectoration, exercise has also been 
shown to improve the ability to complete activities of daily life (ADLs), and thus leads to 
an increased quality of life.10 A study assigned 10 CF patients to a home exercise 
program with the primary outcome of the degree of limitation in completing ADLs. The 
study started with 8 weeks of a control period during which participants were to maintain 
their normal routines, followed by a 12-week cycling program. The daily cycling 
program consisted of 3 minutes of warm-up, 15 minutes of training, and 3 minutes of 
cool-down and was supervised by a physiotherapist 2 days per week. They measured 
exercise tolerance and pulmonary function testing at the start of the 8 weeks, the end of 
the 8 weeks, and every 4 weeks during the cycling program. Participants were then 
instructed to continue their home program for 4 more weeks, and exercise and pulmonary 
testing was measured at completion. They measured ADLs with a survey of 11 activities 
that participants filled out at the start and end of the intervention period. The survey 
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included activities like eating, dressing, bathing, working, traveling, housework, and 
walking.15 
They found a significant increase (P = 0.004) in maximal exercise capacity and 
maximal oxygen uptake (P = 0.008) between the start and end of the 12-week training 
period, but there was no significant change in pulmonary function.10 The lack of a 
significant change may again be the result of a short intervention period of 12 weeks. 
Although this was adequate time to see changes in exercise capacity, the measures of 
lung function likely need a longer period of time to show changes. 
This study found a significant improvement in limitations of ADLs over the 
training period.10 Since we can suggest an increased ability to complete daily activities 
leads to an improved quality of life, this result helps justify our hypothesis that our 
structured exercise program will result in an improved quality of life. Also of importance 
was that, during the follow-up period, 7 patients continued cycling at home and were able 
to maintain or improve their training effects and performance level. This indicates a high 
level of adherence even when patients were not supervised closely. The researchers 
attributed this result to a combination of the prior supervised period and the ages of the 
patients (all > 15 years of age). We hope to have a similar rate of adherence in our study 
since our participants will be of older age, and we will design our intervention to 
encourage adherence through close follow-up during the intervention period. Overall, 
engagement in an exercise program is critical in CF, as evidence shows that poor 
adherence can lead to worsening respiratory disease and increased infections.  
The studies above show the benefits of exercising to improve exercise tolerance, 
lung function, sputum expectoration, and quality of life. The most notable gap in research 
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of these studies is the short length of intervention and follow-up periods. Secondly, many 
of these studies did not measure the frequency of exacerbations or quality of life as 
secondary outcomes. We believe that these are important markers that are directly related 
to each other, as are patient satisfaction and adherence. Our goal is to create a structured 
exercise and ACT program that improves CF clinical outcomes while being realistic for 
the daily lives of patients with CF.  
2.4 Airway Clearance Therapy vs. Exercise  
 
ACT and exercise both improve mucociliary clearance to minimize infections and 
lung function decline.10 Dwyer et al. compared the effects of exercise versus positive 
expiratory pressure (PEP) on anatomical regions of sputum expectoration.16 In this 
crossover study, 15 adults were randomized to one intervention per visit that included 
constant-load treadmill exercise, PEP, or resting breathing. Participants had an initial visit 
for baseline lung function and exercise capacity measurements, and the following 3 visits 
were at least 48 hours apart over 2 weeks. The interventions were performed for 20 
minutes, and measurements were taken before, immediately after, and within 60 minutes 
after. They measured mucus clearance at each time point using a mucus clearance scan of 
the right lung, and they counted the number of coughs during the time periods.  
They found that treadmill exercise had a significant (P < 0.001) increase in mucus 
clearance compared to resting breathing in the intermediate and peripheral regions of the 
right lung, but the central region was not significantly different. A trend towards more 
spontaneous coughs during treadmill exercise compared to resting breathing was also 
noted. PEP therapy led to a significant (P < 0.001) increase in mucus clearance of all 
regions of the right lung (central, intermediate, and peripheral) compared to resting 
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breathing, and there was a significant increase in coughs during PEP compared to resting 
breathing. In comparing treadmill exercise and PEP, treadmill exercise was associated 
with significantly lower mucus clearance in the central region (P < 0.001), but they found 
no significant difference between the intermediate or peripheral regions. They concluded 
that treadmill exercise was significantly better for mucus clearance than resting breathing, 
but PEP was more effective in all lung regions than treadmill exercise.  
A limitation of this study is that the PEP therapy included forced expiratory 
technique (FET, which is relaxed breathing and huffing), while the treadmill exercise did 
not. Researchers noted a significant increase in coughing during PEP compared to 
treadmill exercise, and they attribute this to the FET component.16 Since the resting 
breathing group was not designed as a control group for number of coughs, they were 
unable to determine if the difference in the central region clearance was due to PEP or 
FET. They concluded that PEP therapy (including FET) should be included with exercise 
to increase clearance of the central region. The results of this study show the potential 
benefit of combining exercise and ACT on mucus clearance as opposed to a single 
therapy. Our study is using this concept to create a structured program of both therapies, 
although our primary outcome is FEV1 and not mucus clearance. Also, the short length of 
this study would not have allowed for longitudinal measurements of changes in lung 
function as it was only 2 weeks.  
2.5 Combined Exercise and Airway Clearance Therapy  
 
Several studies, similar to our proposed intervention, have evaluated the effect of 
combining exercise and ACT. A crossover study looked at the acute effect of 60 minutes 
of exercise before physiotherapy (PT) by measuring sputum weight.17 Eight patients 
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participated in 2, non-consecutive days of exercise plus PT and PT alone. Exercise 
consisted of 40 minutes of brisk walking, stretching, cycling, step-ups, jumping, rowing, 
and jogging, and PT included postural drainage, percussion, deep breathing, vibrations, 
and FET. They measured sputum weight during the 40 minutes of exercise and 20 
minutes of rest after (or rest on the PT alone day) and during the 60 minutes of PT plus 
30 minutes after completion. Lung function was also measured at baseline, after exercise 
or rest, after PT, and 30 minutes after PT.  
They found a significant (P = 0.023) difference in total mean sputum weight of 
14g with ACT only and 21.5g with ACT plus exercise. The mean sputum weight from 
the rest period on the PT alone day was 2.6g compared to 7g during the exercise period 
on the exercise plus PT day, although the difference was just outside of significant (P = 
0.053). They did find a significant (P = 0.007) difference in mean sputum weight between 
the PT period on the PT alone day (11.4g) versus the PT period on the PT plus exercise 
day (14.5g). Lastly, they did not find a significant difference in lung function between the 
groups. The authors attribute this to the short study period as opposed to long-term 
follow-up. These results show an added benefit of combining exercise and PT on sputum 
weight, but a longer study would be needed to determine the effect on lung function.  
This study is useful in helping us plan our exercise program. They allowed 
subjects to determine the maximum workload that was comfortably tolerated in contrast 
to measuring a particular goal heart rate or oxygen consumption level. This decision was 
made because they felt it was more similar to clinical practice. We agree that measuring 
outcomes like oxygen consumption is not feasible for a one-year intervention performed 
at home. However, asking subjects to measure their heart rate during exercise would be a 
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more practical approach to ensure the exercise intensity is adequate. Another important 
outcome of this study is that all patients preferred the day of combined exercise and PT 
compared to PT alone. This result is encouraging for the design of our study, as our 
subjects will be asked to perform combined sessions.  
A similar study compared the amount of sputum expectoration between exercise, 
PT, and a combination of both.18 Eighteen subjects were assigned to a random order of 20 
minutes of PT, 20 minutes of cycling, 10 minutes of cycling followed by 10 minutes of 
PT, and 10 minutes of PT followed by 10 minutes of cycling. They chose the 20-minute 
treatment period because they felt it was representative of how long clinically stable 
patients needed to clear secretions. The treatments were performed over 4 days, and each 
was performed twice daily. They weighed expectorated sputum during the 20-minute 
sessions as well as for 30 minutes following and throughout the rest of the day. 
Expiratory flow volumes were also measured before treatment, after treatment, and 30 
minutes post-treatment.  
They found a significantly (P < 0.01) higher amount of sputum production in both 
PT alone or PT plus exercise than with exercise alone. This trend was found in both high 
and low sputum producers in the study. Lung function measures (FEV1 and FVC) were 
not different 30 minutes post-therapy compared to baseline values. However, they did 
find a significant (P < 0.05) increase in the immediate measures of FEV1 after 20 minutes 
of exercise, although it returned to baseline after 30 minutes. In terms of patient 
preference, the study also found that patients preferred exercise followed by PT (P < 
0.001). This was because patients felt that it was the most effective, and researches 
hypothesized that PT after exercise was more relaxing.  
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The results of this study show the importance of including ACT in a daily 
regimen to improve mucus expectoration and begin to show a potential added benefit of 
combination with exercise. Our study will continue with this idea over a long-term period 
as opposed to 4 days. Perhaps the most helpful result of this study in creating our 
structured program is the patient preferences. As we are hoping to improve patient 
experience and quality of life, we will use this information in the order of our ACT and 
exercise with the hope of ultimately increasing adherence. A weakness of this study lies 
in its short intervention period, as well as a lack of a washout period between 
interventions. In their discussion, the authors concluded that patients could be 
recommended to perform a combination of exercise and PT for a daily regimen.  
A study by Salh et al. instructed 19 adult patients to use an at-home cycle and 
perform 10 minutes 5 days per week.19 The patients were to increase their work rate as 
tolerated, and sputum production and lung function were measured at the beginning of 
the study and after 2 months. Additionally, they had a smaller sample of 10 patients in the 
hospital who were instructed to undergo either 15 minutes of PT or 15 minutes of cycling 
followed by a 2-hour period of sputum measurement. They would then perform the other 
therapy, either PT or exercise. Sputum was measured during and after the interventions, 
and this was continued for 2 days. The regimen was then switched to the opposite order 
of PT and exercise for 2 more days. In the larger study, they found a significant increase 
in work capacity, oxygen consumption, and minute ventilation after 2 months of exercise. 
There was not a significant change in FEV1 or sputum weight, although they noted a 
trend in increased sputum production after the intervention period. In the smaller study, 
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PT produced significantly (P < 0.01) more sputum than exercise, and there were no 
significant differences between the order or PT and exercise.  
The larger study showed the benefit of exercise on the outcomes of work capacity 
(P = 0.003), oxygen consumption (P < 0.001), and minute ventilation (P = 0.004), thus 
showing an increase in exercise tolerance. The study had a short intervention period of 2 
months, making it difficult to measure changes in FEV1 longitudinally. The smaller study 
showed similar results to studies mentioned in previous sections with a greater sputum 
production with PT compared to exercise. In regards to the order of PT and exercise, they 
found no difference in their outcomes. A weakness of this study is that they did not 
address patient preference with the order of PT and exercise. Based on these results, 
researchers stated recommending exercise is reasonable as it may prevent a decline in 
lung function due to infected sputum retention. Overall, they believe PT and exercise 
should be complementary therapies.  
In another study on sputum expectoration by Kriemler et al. in Switzerland, 12 
patients were randomized to 3 non-consecutive days of cycling, trampoline, or billiards 
(sham group) followed by PT.20 They participated in 30 minutes of the assigned exercise 
followed by 30 minutes of PT that consisted of 10 minutes of an oscillator device and 20 
minutes of deep maximal inspiration and slow exhalation. After each treatment, 
researchers measured sputum expectoration and FEV1. They found a significantly higher 
amount of sputum expectoration after the trampoline compared to billiards (P = 0.021) 
and a trend of increased sputum expectoration after cycling compared to billiards (P = 
0.074). Additionally, they found a similar amount of sputum expectoration after all PT 
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sessions regardless of the exercise modality used. However, they did not find a difference 
in the FEV1 between any of the groups.  
This study is similar to our proposed study in terms of the combined exercise and 
PT program but differs in its crossover design and short study period. The short study 
period likely contributes to the findings of no significant difference in FEV1. Again, we 
expect that a longer treatment period is required to see significant changes in lung 
function.  
In a crossover study by Reix et al., 34 pediatric CF patients participated both in 
one session of 20 minutes of ACT (control) and one session of 20 minutes of combined 
exercise and forced expiratory techniques (intervention).21 These sessions were 
performed on non-consecutive days. They found a significant improvement in FEV1 after 
the intervention session compared to the control session. The relative improvement after 
the intervention was 2.7% with a significant mean difference of 3.2% (95% CI 0.5 to 6.0) 
compared to the control. Patients also reported a significantly higher satisfaction score 
with the intervention group compared to control.  
The results of this study show that there may be even an immediate effect on lung 
function by combining ACT and exercise as opposed to ACT alone. Although the 
researchers note the lower end (0.5%) of the confidence interval is not clinically 
important, the upper end (6%) is a clinically important difference. The largest limitation 
of this study is the design of only 1 intervention session because it does not provide data 
on how long the changes are sustained. Our study utilizes the same concept of combined 
ACT and exercise, but it will be performed regularly over 1 year to gather longitudinal 
results. The higher satisfaction scores with the inclusion of exercise are also encouraging 
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for our study intervention. With improved patient satisfaction comes an improved quality 
of life and treatment adherence, both of which are goals with our study. 
2.6 FEV1 and Secondary Outcomes (Exacerbations and Quality of Life)  
 
 Since FEV1 decline marks disease progression in CF, it is closely related to 
exacerbations and quality of life. As the number of exacerbations increases, FEV1 tends 
to decrease.22 Using information from the CF Patient Registry, the relationship between 
increasing exacerbation rate and decreasing lung function is linear.23 This means that 
patients with a higher FEV1, indicating better lung function, have a decreased incidence 
of exacerbations. One study followed patients over 3 years and found that those with less 
than 1 exacerbation per year had a mean FEV1 change of -4.85%, while those with 1-2 
exacerbations had a change of -5.44%, and patients with more than 2 exacerbations had a 
change of -6.49%.22 They also found that patients with more than 2 exacerbations per 
year had a lower baseline FEV1 as well as a more severe progression in FEV1 decline 
compared to those with fewer exacerbations. Additionally, these patients had a 
significantly increased risk of death within 3 years. This information demonstrates the 
importance of preserving lung function and limiting the number of exacerbations per 
year.  
Multiple studies have also looked at the impact of cystic fibrosis on quality of life. 
Exacerbations are associated with significant decreases in the physical well-being and 
psychosocial quality of life of CF subjects.24 Bradley et al. compared quality of life 
between people with CF with no pulmonary exacerbation, mild exacerbation, and severe 
exacerbation.25 They found that the more severe the exacerbation, the lower the quality of 
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life in multiple aspects like physical function, role limitations, emotional functioning, and 
social functioning.  
A systematic review of CF and quality of life looked at studies that used the 
Cystic Fibrosis Questionnaire – Revised (CFQ-R).26 After evaluating 28 articles, they 
concluded that a lower FEV1 has a correlation with physical functioning, respiratory 
symptoms, and treatment burden. They also found a significant association between 
exacerbations and lower CFQ-R scores. They concluded that since FEV1 and pulmonary 
exacerbations have the strongest impact on the health-related quality of life for those with 
CF, these are aspects that must be addressed clinically. In our study, we will be looking at 
these outcomes to determine the benefit of a structured exercise and ACT program. Our 
goal is to ultimately improve lung function and decrease exacerbations to improve quality 
of life for people with CF.  
2.7 Adherence to Therapy  
 
Adherence can be defined as an “active, voluntary, collaborative involvement of 
the patient in a mutually acceptable course of behavior to produce a desired preventative 
or therapeutic result.” 27Adherence to therapy is challenging with CF because as lung 
function deteriorates over time, the complexity of the therapy increases. Patients are also 
living longer, and as a result, they face added social and professional responsibilities in 
their daily lives. This has made gathering information on treatment adherence even more 
important.  
In general, studies have shown that adherence declines with increasing treatment 
time and complexity.27 The treatment regimen for CF is time-consuming and includes 
oral or inhaled antibiotics, pancreatic enzymes, mucolytic agents, vitamin supplements, 
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and physiotherapy treatments. One study found the most common reason reported for 
non-adherence was forgetfulness followed by the time and effort commitment.28 
Although it can be difficult to measure adherence due to reporting, studies have found 
that in CF, antibiotic adherence is around 80-95%, nebulized medication and pancreatic 
enzyme adherence is 65-80%, and adherence to vitamins, diet, exercise, and 
physiotherapy is 40-55%.27 These numbers show that the components of our intervention, 
including exercise and physiotherapy, have the lowest adherence rates. This information 
is important for us to account for when designing our structured program. Our goal is to 
create a program that can be implemented into the daily lives of people with CF without 
significantly increasing their treatment burden. We will encourage adherence during the 
intervention period with close follow-up that could be reproducible outside of the study 
through CF clinics.  
To address adherence, we will implement a similar concept to a study by 
Schneiderman-Walker et al.29 This study had 72 participants who were randomized either 
to an exercise group or the control group. The exercise group was instructed to partake in 
aerobic activity for 20 minutes at least 3 times weekly over 3 years. They had participants 
fill out a daily journal that was collected at each 3-month visit. The pages listed the date, 
type of activity, duration in minutes, and the intensity of the exercise. They also had 
phone calls with the participants every 4-6 weeks. Over 3 years, the study found that the 
mean scores in exercise compliance did not vary, and the exercise group had consistently 
higher amounts of activity compared to control. These results show that the methods used 
were effective, as they did not find a decline in adherence over the 3 years.  
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 Another way we are designing this study to increase adherence and 
generalizability is by allowing participants to make some decisions in their intervention. 
One study measured change in lung function over 3 years between those who exercise 
regularly and those who do not.30 They allowed the intervention group to choose their 
method of exercise, which included the gym, dance, and jogging. Their justification for 
the decision was because patient adherence improves when patient preference is 
considered in the treatment plans. Despite this, they still found a significant difference 
between the two groups in FEV1. In the exercise group, annual FEV1% decline was 0.4% 
compared to 1.6% in the control group. Unfortunately, they do not specifically describe 
the parameters of the length and frequency of  “regular exercise,” but they do mention 
that the exercise was mostly all aerobic and at least 3 times weekly.  
 Using the information from this study, it seems feasible for participants to choose 
their method of exercise from a list of acceptable modalities. An additional consideration 
is the decision between supervised, partially supervised, and unsupervised participation in 
ACT and exercise. Again in line with creating a feasible regimen, supervised exercise 
and ACT would greatly increase the costs and personnel time required for a study, as well 
as impair generalizability because regularly supervised exercise and ACT is not practical 
in the daily lives of those with CF. Another study of 2 years allowed the exercise group to 
choose their methods as long as they increased their activity by three 60-minute sessions 
per week.31 They continued to have their appointments every 3 months. The study was 
able to conclude that a partially supervised and individual-based home exercise program 
may be sufficient in changing activity levels for patients. They concluded that the type of 
activity likely does not matter in regards to the positive effects. Although less supervision 
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may reduce the compliance of participants, we plan to mitigate this through the measures 
discussed above including allowing individual preferences, monthly phone calls, and 
daily journals.  
2.8 Possible Confounders  
 
 Lung function is a variable measurement depending on many factors in people 
with CF. One possible confounding factor on lung function is age.32 In general, patients 
with CF see a decline in FEV1 percent predicted by 2% annually.
22 One study followed 
lung function in people with CF for 10 years.32 Overall, they found an 8.8% decline in 
FEV1%. Another study measured FEV1 over 5 years and found an average total decline 
of 11.9%. 33 These studies demonstrate a decline in lung function with increasing age, 
which is important to be aware of in our study. As our participants will have a wide age 
range, we should expect a wide range of baseline FEV1 measurements.  
Also of note, the decline in lung function seems to plateau after reaching a certain 
age.12 One study showed the steepest decline to be during childhood and early adulthood 
and became a modest decline until the age of 30 when it became more stable. This will 
play a role in our study since our study population is adults. For participants over the age 
of 30, their natural lung function decline will be less than those under 30. In our study, 
this means that those who are older will likely have smaller sizes of effect from our 
intervention compared to those who are younger.34 To address this, we will match 
subjects by age and baseline FEV1 during analysis. 
 Along with age, lung function varies based on the type of CF-causing mutation.35 
In CF, these mutations are categorized based on the amount of CFTR protein created and 
its functional ability at the cell surface.36 The most common CF-causing mutation is 
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Phe508del, a class II mutation.37 In subjects harboring this mutation, CFTR protein is 
synthesized, but it is misfolded and degraded by proteases before reaching the cell 
surface, resulting in minimal to no CFTR function. Those with class I or II CFTR 
mutations on both CFTR alleles have significantly lower FEV1 compared to those with at 
least one III, IV, or V mutation (milder CF-causing mutations with residual CFTR 
function).38 These patients also had a more significant decline in their lung function 
during follow-up. Additionally, those with class I or II mutations on both alleles had a 
significantly higher rate of Pseudomonas colonization.  
 Another possible confounder with lung function is the patients’ status of bacterial 
colonization. The most common organism in CF is Pseudomonas aeruginosa.39 Once a 
person with CF is colonized with P. aeruginosa, it marks a progressive decline in lung 
function.40 For example, a study found a significant (P < 0.0001) decline in FEV1 in 
patients who were colonized with P. aeruginosa.41 On average, these patients had a 13% 
lower FEV1 than those who were not infected. The other opportunistic organism 
frequently associated with CF is Burkholderia cepacia.42 A study followed the lung 
function of patients with CF who were either colonized with Burkholderia and 
Pseudomonas, Pseudomonas alone, or neither for 8 years.40 They found that those who 
were not colonized with either had significantly higher FEV1% compared to both of the 
other groups. They also found a significant difference in the FEV1 decline between those 
with both organisms (-5.4%) versus Pseudomonas alone (-3.9%). This study overall 
showed that additional infection with Burkholderia led to an accelerated decline in lung 
function compared to those with Pseudomonas alone. We must be aware of this during 
our study because if our participants become infected with either organism during the 
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study, we can expect to see a greater decline in their lung function. In order to address 
this potential confounder, we will match subjects according to sputum microbiology 
whenever possible in our analysis.  
 Lastly and perhaps most importantly, we considered the potential impact of novel 
triple-combination CFTR modulator therapies in our study. A treatment combining CFTR 
modulators (Elexacaftor, Tezacaftor, and Ivacaftor), known commercially as Trikafta, 
became available in 2019.43 Phase 3 trials in patients with the f508del mutation showed a 
significant improvement in FEV1 predicted with a mean increase of 10% after 4 weeks.
44 
There was also a significant improvement in CFQ-R scores with a mean increase of 16 
points (4 points is set as the minimal clinically important difference). As 90% of people 
with CF are either homozygous or heterozygous for the f508del mutation,45 the majority 
of patients have the potential to experience substantial improvements in lung function and 
quality of life. As a result, those starting triple therapy will see great increases in their 
lung function, thus creating a possible confounder in our study.  
 The phase 3 trial for Trikafta had a duration of 4 weeks, which was noted to be 
shorter than previous phase 3 studies for CFTR modulators that used 24 weeks.44 
However, this was chosen because previous studies of other CFTR modulators, including 
Tezacaftor-Ivacaftor,46 Lumacaftor-Ivacaftor,47 and Ivacaftor,48 all showed that the 
greatest changes in FEV1 occurred within the first 4 weeks of treatment and were then 
sustained.44 Therefore, we will assume those who have been on triple combination 
therapy for longer than 4 weeks have already seen the largest improvement in their FEV1, 
and the medication should no longer be a confounder. Of note, a benefit of the 
introduction of triple combination therapy is that a greater amount of patients will have a 
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higher lung function that allows them to partake in exercise. This will increase the 
number of patients that are medically stable to participate in our study.  
2.9 Review of Relevant Methodology  
2.9.1 Measuring FEV1   
All of the reviewed studies that measured lung function used spirometry. 
Spirometry is a form of pulmonary function testing (PFT) that measures volume against 
time.49 PFTs are regularly used in medicine to determine the presence of airflow 
obstruction to help make a diagnosis. The patient is instructed to take a full inhalation and 
then a forceful expiration for as long and as quickly as they are able. Along with several 
other measures, this results in the FEV1, the volume of air exhaled in the first second of 
forceful expiration. FEV1 is used to monitor disease progression and treatment response 
of CF,50 therefore, it is an ideal measurement to follow as a primary outcome.  
FEV1 is often expressed as a percent predicted to standardize the results across 
different ages, heights, sex, and ethnicities.50 There are several equations used to 
calculate the percent predicted. One study used the percentage of the FEV1 of the vital 
capacity,11 one used Sherril,9 another used Tammeling,10 and one used Quanjer20 for their 
calculations. The Yale Adult CF Program uses the third National Health and Nutrition 
Examination Survey (NHANES III) equation. This equation comes from a survey that 
collected spirometry data from a sample size of 7,429 people in the United States.51 The 
data was used to create reference equations for pulmonary function for Caucasians, 
African-Americans, and Mexican-Americans based on age, sex, and height. This study 
has multiple strengths, including that it was conducted nationwide and had a diverse 
 
 33 
sample population. As a result, the equations produced are likely to be representative of 
the population.  
The difficulty in following FEV1 lies in its variability. There are variations seen 
when FEV1 is followed over time due to 3 reasons: variability between patients, within a 
patient, and due to measurement.50 This shows why some of the short-term studies may 
not have provided enough data points to ensure that changes, or a lack of change, were 
not due to this variability. Since our study intervention period is 1 year, we will have 
more data points to look at overall trends, and thus each individual may serve as his/her 
own reference, which will ensure this variability will not have as large of an impact on 
our results. To address this issue, one study had each subject perform 3 rounds of 
spirometry, and they used the highest results in their data.17 This sounds like a reasonable 
way to decrease measurement errors, although if the source of the error is the person 
assisting with performing spirometry, then this method may not help. Therefore, most of 
the reviewed studies also had the same person assisting the patients with their spirometry 
to minimize variability between users.  
According to the American Thoracic Society Standardization Guidelines for 
Spirometry, the spirometry maneuver should be performed at least 3 times and a 
maximum of 8 times.52 The additional maneuvers should be performed if the FEV1 values 
are not repeatable between the first 3; this is defined as the difference between the 2 
largest FEV1 measurements must be less than or equal to 0.150L. These guidelines are 
important to follow so that all spirometry measurements are performed the same, thus 
decreasing the amount of variability in our results.  
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2.9.2 Survey to Measure Quality of Life  
There are many surveys to measure quality of life. One example is the Cystic 
Fibrosis Questionnaire-Revised (CFQ-R) designed for patients with CF who are 14 years 
or older.53 This survey is ideal for measuring health-related quality of life for several 
reasons. The first is that the CFQ-R is specifically designed for people with CF. The 
second reason is that the CFQ-R is the most accepted survey to measure quality of life in 
patients with CF.26 For example, multiple clinical trials for new CF medications, 
including the phase 3 trial of Trikafta,44 used the CFQ-R.53 It is also the survey used at 
our primary study location at The Yale Adult CF Program, and patients already fill the 
CFQ-R out at each quarterly CF appointment.  
2.9.3 Inclusion and Exclusion Criteria  
 Most studies reviewed and discussed above excluded participants with previous 
lung transplant and those who were not deemed clinically stable by their CF provider. 
Several of the studies excluded those colonized with B. cepacia. One study excluded 
those with non-CF related chronic conditions that would pose a risk with exercising.9 
This included esophageal varices, pulmonary bullae, a drop in arterial oxygen saturation 
below 80%, or signs of pulmonary hypertension on EKG. These criteria are all 
reasonable measures to ensure the safety of the participants in undertaking an exercise 
program. Another important parameter for participation is baseline FEV1 values. The 
studies reviewed with an FEV1 cutoff used either greater than or equal to 35% predicted 
or 40% predicted. Since these values mark severely declined lung function, it is more 
likely that the subject would not be able to safely tolerate an increase in physical activity.  
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 Other inclusion criteria for all studies included a diagnosis of CF, however, the 
definition of diagnosis varied between studies. Studies that listed specific criteria for 
diagnosis included abnormal sweat test, typical pulmonary or digestive symptoms, family 
history of CF, and genetic testing. These criteria are similar to the diagnosis criteria 
outlined on DynaMed for CF, which is made by at least 1 of the 3 following criteria: 1) 
Elevated sweat chloride concentration, 2) 2 disease defining mutations in CFTR gene, or 
3) Organ dysfunction such as lung or gastrointestinal. As our study participants are 
subjects with a confirmed diagnosis of CF recruited from the Yale Adult CF Program 
Clinic, we will adopt their definition of a CF diagnosis, which is also similar. This 
includes a clinical presentation consistent with CF and CFTR sequencing that shows CF 
causing mutations in both CFTR alleles.  
2.9.4 Recruitment  
 All but one of the studies reviewed recruited study participants from either one or 
multiple CF centers based on their own willingness. One study also used advertisements 
in a CF newsletter.16 CF patients attend their clinic every 3 months, so these frequent 
visits pose a feasible method for recruitment within the centers. Although not mentioned 
in any reviewed studies, another option to increase the number of participants would be 
to work with the Cystic Fibrosis Therapeutics Development Network (CF TDN). The 
TDN was established by the Cystic Fibrosis Foundation to create access to a larger 
patient population for therapeutic trials.54 The CF TDN consists of 91 accredited CF care 
centers around the US.55 If more subjects were needed for our research, we could contact 
the TDN Coordinating Center to present our study and request that they notify sites that 
may be interested in joining. The design of our study would be easily implemented in any 
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CF clinic because it utilizes the routinely used FEV1 and health-related quality of life 
measurements already applied during routine clinic visits. Therefore, other locations that 
may participate in the study would not need additional equipment or measurements.  
2.9.5 Sample Size   
 Although FEV1 is a frequently used outcome measure in CF trials, it is difficult to 
determine a minimal clinically important difference (MCID) for the population.56 Instead, 
it is argued that the MCID should be based on each individual as lung function varies 
greatly with CF. Since this is difficult to standardize, a statistically significant difference 
between the intervention and control groups is usually considered a successful trial as 
opposed to reaching a specific MCID. This concept is reasonable, but it does pose 
additional difficulty in calculating a sample size based on an effect size. Therefore, we 
must use the results of previous studies to calculate our sample size as opposed to an 
MCID. Of the reviewed studies that combined ACT and exercise, the sample sizes ranged 
from 817 to 34.21 Although these sample sizes are all small, the studies found statistical 
significance in some or all of their outcomes.  
2.9.6 Intervention  
 In the reviewed studies with an intervention of both exercise and ACT, the 
specifications of the regimen varied. The interventions consisted of either: 40 minutes of 
exercise prior to 25-40 minutes of ACT,17 30 minutes of exercise followed by 30 minutes 
of ACT,20 10 minutes of exercise and 10 minutes of ACT compared to the reverse order 
of 10 minutes of ACT and 10 minutes of exercise,18 or 3 periods of 5 minutes of aerobic 
exercise spaced by 1.5 minutes of ACT.21 Although all of these studies had a primary 
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outcome of sputum expectoration instead of lung function, they all produced significant 
results.  
 In the studies that focused only on the longitudinal effects of exercise and not 
ACT, the regimen again varied. The interventions consisted of: 1 hour of training 
(stretching, walking/jogging, and recreational activities) 3 times weekly,11 30-45 minutes 
of activity 3 times weekly,9 and 21 minutes of cycling daily.10 Two of the studies showed 
significant improvements in exercise tolerance with the intervention, 10,11 and one study 
showed a significant improvement in FEV1 with the intervention. 
9 Based on these 
results, all of these exercise interventions could have a significant impact on the lung 
function of patients with CF.  
 Several of these studies implemented measures to ensure a specific intensity of 
exercise. One study had patients palpate their pulse and encouraged a heart rate of 70-
85% of their maximal heart rate,11 another used 70% of maximum heart rate,10 and one 
targeted a heart rate of 140-160 beats per minute.20 Five of the studies used VO2 levels of 
65%,9 60%,13,16,18 and 50%19 of the patients' peak oxygen capacity to measure exercise 
capacity. Of note, 2 of the 3 studies that lasted at least 3 months used heart rate as 
opposed to VO2 levels to quantify the exercise,
10,11 and the study that used VO2 used 
watches that measured heart rate to correlate to their target VO2.
9 Perhaps this suggests 
that for longer-term studies, heart rate is a more feasible target to follow, especially for 
patients at home, as opposed to VO2. One study addressed this issue by allowing patients 
to subjectively work at a level they could tolerate.17 They chose this method because it 
better represented a clinical situation, and they were still able to find a significant 
improvement in sputum expectoration with exercise before ACT.  
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2.9.7 Adverse Events  
 Although exercise is generally recommended as a therapy for CF, no physical 
activity comes without risks of possible harm to the body. One study, to identify adverse 
events from exercise in those with CF, sent out questionnaires to patients regarding this 
issue.57 The survey included pneumothorax, loss of consciousness, and acute dyspnea and 
cough (asthma attack) after exercise. They were also able to write in their own adverse 
events. The patient survey was completed by 256 patients with a mean weekly average of 
3.6 hours of exercise. 67% of the patients had experienced no adverse events, 22% had an 
asthma attack, 6% had an injury, 4% had a pneumothorax, and 1% had a loss of 
consciousness. Of the answers written in by patients, 4% had worsening arthritis with 
exercise, 3% had hemoptysis, and 1% had hypoglycemia with exercise. In summary, this 
study found low incidences of adverse events related to exercise in those with CF. 
Of the studies discussed that mentioned adverse events, most had none to 
report.9,11,16,18 These studies specifically mentioned the absence of cardiac and orthopedic 
complications, injuries, pneumothorax, asthma attacks, hypoglycemia, heart rate, and 
oxygen saturation. One study had 5 participants with adverse events, which were not 
statistically significant between the intervention and control group.21 This included 
fatigue, breathlessness, and oxygen desaturation below 92%, and these resolved quickly 
with rest. Overall, the risk of any of these possible adverse events is low; however, they 
remain important to monitor during our study to ensure the safety of the participants.  
2.10 Conclusion  
 Based on the studies discussed in this section, the individual benefits of ACT and 
exercise as treatment modalities in CF are clear. However, there is limited data on the 
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long-term effects of a combined regimen. Available studies combining ACT and exercise 
are short-term and often focused on sputum production as opposed to lung function. 
These studies, however, have demonstrated the benefit of ACT in preventing 
exacerbations in order to better preserve lung function and quality of life. As we note 
above, sputum production is a frequently measured outcome, but is fraught by variability 
and technical difficulties. More importantly, measurements of sputum clearance may not 
directly reflect the clinical impact of exercise and ACT on lung function and quality of 
life. Therefore, we concentrate on clinically relevant measurements of FEV1 and quality 
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Chapter 3 – Study Methods  
3.1 Study Design 
 
Our study will be a prospective randomized controlled trial. Patients will be 
randomized to either structured ACT and exercise or unstructured ACT and exercise. The 
CF providers and respiratory therapists performing spirometry will be blinded to the 
intervention. The intervention period will last 1 year, and subjects will not crossover to 
the other intervention. Outcome measurements will occur at 0, 3, 6, 9, and 12 months. At 
the end of the study, participants are free to alter their exercise regimens as desired.  
Figure 1: Proposed Study Design  
 
3.2 Study Population and Sampling 
 
The study population will be adult patients (≥18 years of age) with a confirmed 
diagnosis of CF from The Yale Adult CF Program within the Yale CF Care Center. 
Providers at the clinic will be approached to discuss the study, and they will be asked to 
recruit patients that fit our eligibility criteria. This sampling method will aim to ensure 
that the subjects recruited regularly attend their CF appointments. This is important for 
several reasons; the first is that those who regularly go to their appointments will have 
more contact with their providers, thus making it easier for the provider to deem the 
patient is safe to participate. Second, it will target patients who are motivated and actively 
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participate in their own care. Since this study is evaluating an at-home program, it is 
likely that those who would participate outside the study would also only be those who 
are more motivated. Lastly, if patients attended their previous appointments, it is more 
likely they will attend future appointments at which study measurements will take place. 
Also, those who attend appointments regularly will have closer follow-up to adjust their 
other treatments as needed, which is important for their safety.  
3.3 Inclusion  
 Inclusion criteria will be given to the providers at the CF clinic to screen for 
eligible patients – Patients must be 18 years of age and older and deemed stable by their 
CF provider to exercise and participate in the study. Also, patients must already use a 
form of ACT before starting the study. Women will not be excluded if already pregnant 
or if they become pregnant during the study. Patients will be recruited regardless of race 
to best represent the population of those with CF, although it should be noted the disease 
is more prevalent in Caucasians. Patients who already exercise and those who do not may 
be included, as they will be randomized to the intervention.  
3.4 Exclusion  
Patients with an FEV1 < 40% will be excluded from the study. Those who are 
post lung transplant will also be excluded. Patients who have comorbidities other than CF 
that inhibit their ability to exercise or affect their lung function will be excluded. This 
includes diagnoses of pulmonary hypertension, heart failure, and other advanced lung 
diseases like COPD, asthma, and idiopathic pulmonary fibrosis. Lastly, those who have 
started taking any CFTR modulator medications within the last 4 weeks will be excluded 
(those who have been on a stable dose for longer than 4 weeks will be eligible). These 
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exclusion criteria are primarily for the safety of the patients participating in the study to 
decrease the chance of any adverse events with exercise. The criteria will also increase 
the likelihood that changes in lung function are a result of the intervention as opposed to 
other causes. Children are not included in this study because they have different patterns 
of lung function decline compared to adults, and the CFQ-R is designed for 14 years of 
age and older.  
3.5 Subject Protection and Confidentiality 
 
 Before the initiation of this study, we will first gain approval by the Yale University 
Institutional Review Board (IRB). All participants in the study must complete and sign our 
informed consent form. The form will cover important information for the patient and will 
be reviewed with study recruitment staff. The consent form will describe the procedures of 
the study and the potential risks and benefits. A description of patient confidentiality and 
privacy will be included to explain the handling of patient information during the study. 
Lastly, the patient will be able to ask any questions regarding the study, and they may take 
time to consider joining before signing the form. A sample of the consent form can be found 
in Appendix A.  The study protocol and patient confidentiality will comply with the Health 
Insurance Portability and Accountability Act (HIPAA) regulations. Patient information will 
be de-identified and kept confidential. Participation in the study is entirely voluntary, and 
participants may withdraw from the study at any time without affecting the care they receive 






 Recruitment will take place over 1 year at The Yale Adult CF Program within The 
Yale CF Care Center. Since patients attend the CF clinic every 3 months, this will provide a 
large number of potential participants.  The providers at the CF clinic will be provided with 
study details and inclusion/exclusion criteria and asked to recruit eligible patients. Flyers 
will also be sent to the patients of the clinic with information regarding the study and 
information on how to enroll. A sample flyer can be found in Appendix B. Additionally, if 
more participants are needed, we may recruit from the Adult Cystic Fibrosis Clinic at 
Hartford Hospital. This would create a larger pool of patients to sample from while 
keeping in proximity to our primary site. Lastly, the study may be presented to the Cystic 
Fibrosis Therapeutics Development Network to further recruit participants from CF clinics 
around the United States.  
3.7 Study Variables and Measures 
 
The independent variable of this study is the regimen of exercise and ACT. The 
subjects will be separated into 2 groups: Either structured exercise and ACT 
(intervention) or non-structured exercise and ACT (control). The main outcome and 
dependent variable of this study is FEV1 percent predicted. This will be measured at 
baseline as well as at each quarterly visit during the year. FEV1 will be measured with 
spirometry using the most up-to-date American Thoracic Society guidelines and 
expressed as percent predicted using the NHANES III equation. Respiratory therapists 
within the CF clinic will perform spirometry. 
Secondary outcomes will include exacerbation frequency and quality of life. 
Exacerbations will be assessed using medical records through an Epic chart review upon 
completion of the intervention. An exacerbation will be defined using criteria by Fuchs et 
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al.: “A patient treated with parenteral antibiotics for any 4 of the following 12 signs or 
symptoms: change in sputum; new or increased hemoptysis; increased cough; increased 
dyspnea; malaise, fatigue, or lethargy; temperature above 38 °C; anorexia or weight loss; 
sinus pain or tenderness; change in sinus discharge; change in physical examination of 
the chest; decrease in pulmonary function by 10 percent or more from a previously 
recorded value; or radiographic changes indicative of pulmonary infection.”1 Quality of 
life will be measured using the Cystic Fibrosis Questionnaire-Revised (CFQ-R). A copy 
of the survey can be found in Appendix C. The survey will be completed at baseline and 
each 3-month clinic visit during the year.    
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3.8 Methodology Considerations  
3.8.1 Experimental Protocol 
 The study will consist of a 1-year intervention period. Before starting the 
intervention, study-recruiting personnel will discuss exercise parameters with the 
subjects. They will be instructed to choose their preferred type of exercise from the 
provided list (Appendix D). To ensure subjects are exercising at a high intensity, they 
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will be instructed to record their heart rate in their journal before starting exercise, at 15 
minutes of exercise, and upon completing 30 minutes of exercise. Study personnel will 
demonstrate how to calculate heart rate by counting the heart rate for 15 seconds and 
multiplying that number by 4. Subjects will be provided their target heart rate and asked 
to increase their intensity if their heart rate is below target when checked at the 15-minute 
point. Instructions will also be written in the journal, which can be found in Appendix E. 
Calculations for target heart rate can be found in Appendix F.  
Subjects randomized to structured ACT and exercise will perform 30 minutes of 
exercise immediately followed by ACT 3 times weekly. The length and modality of ACT 
will be performed according to the CF provider’s recommendations. If the subject 
performs more than 1 session of ACT in a day, they may choose which session to 
combine with exercise. Upon completing each session, the participant will fill out their 
journal entry for the day. The journal should be filled out every day whether they 
exercised or not. For those assigned to the non-structured program, they will also be 
instructed to exercise 3 times weekly, but it should be separated by at least 2 hours from 
an ACT session. ACT should be performed according to the provider’s 
recommendations.  
Figure 2. Sample Weekly Schedule of ACT and Exercise  
 
3.8.2 Blinding of Intervention 
Blinding of the intervention to the study subjects is not feasible given their active 
participation in the intervention. The assignment of the intervention will be blinded to the 
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respiratory therapist performing spirometry measurements. Providers will also be blinded 
to the intervention. Subjects will be asked to keep their intervention confidential from 
their providers.  
3.8.3 Blinding of Outcome 
  The subjects will not be blinded to the outcomes of FEV1% or exacerbation 
frequencies. As the study is longitudinal, they should be aware of their lung function 
during the year, and they will already be aware of their exacerbations. Subjects will be 
blinded to their CFQ-R scores. Providers will not be blinded to any of the outcome 
measures for the safety of the participants. This will allow providers to modify treatment 
regimens, if needed, due to unexpected changes in lung function or clinical condition.  
3.8.4 Assignment of Intervention  
 Intervention will be assigned using randomizeR software.  
 
3.8.5 Adherence 
  Adherence will be monitored throughout the study. At home, patients will use a 
daily journal to log modality and time spent on exercise and ACT. These logs are to be 
brought to every appointment to be reviewed and discussed. During the months the 
patient does not have an appointment, they will receive a monthly phone call from study 
personnel to discuss adherence and answer any questions.  
3.8.6 Monitoring of Adverse Events 
 Before beginning the study, patients will be made aware of the very low risk of 
possible adverse events such as physical injury, an increase in dyspnea or coughing, 
hypoglycemia, loss of consciousness, worsening of arthritis, and pneumothorax. At each 
office appointment, in addition to spirometry, vitals (blood pressure, heart rate, and 
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oxygen saturation) will be measured and compared to previous vitals. Patients will also 
be asked if they have noticed any changes in their health or if they have any concerns at 
every visit and during every phone call, and they will be encouraged to document these in 
their logs. Patients will be instructed to immediately discontinue exercise if they feel that 
they are unable to complete a session. The phone number to their CF provider will be 
given to all patients to call if they have any questions or concerns.  
3.9 Data Collection 
 
 Data collection will take place for 1 year. During this time, participants will 
continue to have quarterly appointments. At each of these appointments, all participants 
will perform spirometry with a respiratory therapist to measure FEV1. They will also 
complete the CFQ-R to evaluate their health-related quality of life. Data collection on 
exacerbations will take place at the end of the study based on chart review for the year of 
the intervention period.  
3.10 Sample Size Calculation 
 
The previous studies that combined exercise and ACT used a short-term outcome 
follow-up, and did not find significant differences in FEV1 to inform our sample size 
calculations for a 1 year intervention design. Therefore, we used a study with a similar 
exercise intervention and a longer follow-up period to calculate our sample size. Our 
sample size calculation is based on change in FEV1 percent predicted over 6 months in 
adults with CF from a study by Kriemler et al.2 The exercise intervention is similar with 
30 minutes of exercise 3 times weekly, and subjects received monthly phone calls in 
addition to quarterly appointments. The exercise group had an increase in FEV1 of 
5.76±3.7% over 6 months, and the control group had a decrease in FEV1 of -4.42±14.7%. 
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Using these numbers, and assuming an alpha of 0.05 and power of 90% with a two-tailed 
hypothesis, we calculated a sample size of 50. As this study does not directly include 
ACT as part of the intervention, and it compares an exercise group to a control group 
without specific exercise instructions, in addition to increasing power to 90%, we will 
add 10 more subjects to each arm to account for this difference in study design. Also, to 
accommodate for a 10% dropout rate, we aim to recruit a total of 77 participants. The 
sample size calculation can be found in Appendix G.  
3.11 Analysis 
 
 The study population will be characterized using descriptive statistics for 
parameters including age, sex, race, baseline FEV1, and baseline CFQ-R score (Table 2). 
This will utilize both unpaired Student’s t-tests for continuous variables and Chi-squared 
tests for categorical variables. All analyses will be performed using the intention to treat 
principle, and statistical significance will be designated as P < 0.05. The outcomes of 
FEV1 % predicted, exacerbation frequency, and QOL scores are all continuous variables 
and will be described as means with standard deviations. Unpaired Student’s t-tests will 
be used to compare the change in FEV1, change in CFQ-R score, and the difference in 
exacerbation frequency between the 2 groups. Paired Student’s t-tests will be used to 
compare the change in FEV1 CFQ-R score within the same subjects from baseline. If data 
is not normally distributed, then paired and unpaired Wilcoxon’s rank-sum tests will be 
used instead. As FEV1 and CFQ-R scores will be measured quarterly, those time points 
will be compared using unpaired Student’s t-tests. To look at the effect of the 
intervention in specific groups, results will also be stratified by CFTR genotype, 
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colonization with Pseudomonas aeruginosa, colonization with Burkholderia cepacia, and 
type of CFTR modulator medication used.  
Table 2. Sample Table of Baseline Characteristics of Subjects    
Characteristic Structured Non-Structured P value  
Sample Size (n)    
Gender (% F, %M, % Other)    
Age (Years)    
Race (White, African American, 
Hispanic, Other) 
   
FEV1 (% Predicted)    
CFQ-R Score (Points)    
 
3.12 Timeline and Resources 
 
 Before recruitment begins, the Human Investigation Committee (HIC) process is 
estimated to take 2-3 months. The recruitment phase and intervention phase will be a 
total of 2 years. Upon completion of the intervention period, data analysis is estimated to 
take 2-3 months.  
Figure 3. Proposed Study Phases 
 
 
The personnel required to complete this study includes the CF team who the 
patient normally sees every 3 months, including the physician and the respiratory 
therapist to perform the spirometry, and a research assistant for recruitment assistance 
and data entry. The principal investigator will also perform recruitment assistance as well 
as conduct the monthly phone calls. As the study is utilizing the patients’ already 
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Chapter 4 – Conclusion  
 
4.1 Advantages and Disadvantages   
 
 Our proposed study has several advantages over previous studies that investigated 
the relationships between lung function, exercise, and ACT in patients with CF. First, our 
intervention period of 1 year is longer than most studies and will provide a longitudinal 
look at FEV1 measurements to ensure sustained results. As a result, our findings will give 
greater insight into the long-term benefits of ACT and exercise as opposed to their 
immediate effects. Additionally, our study takes advantage of the already scheduled 
appointments that patients with CF have quarterly, thus decreasing the time burden of 
appointments for our participants.  
 Another strength of this study is that we are aiming to create an exercise and ACT 
regimen that could feasibly be implemented into the lives of those with CF. In contrast to 
studies that have directly supervised or closely monitored exercise sessions, our exercise 
regimen will be performed individually. Also, ACT will be performed with the 
participants’ modality of choice and for the amount of time instructed by their providers. 
Overall, we believe this makes the intervention more generalizable to those with CF 
because it does not require additional resources like trainers or new ACT modalities.  
An important limitation of our study design is that a less-regulated structure 
allows for variability in the intensity of the exercise performed by the participants, and 
we must rely on self-reported adherence. This also means that participants will be 
completing different forms of ACT for different time periods. However, the different 
forms of ACT should not cause a significant difference in change in lung function, as 
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previous studies have shown no significant differences between the modalities. 
Furthermore, since this study takes place over 1 year and subjects have varying lung 
function status, it would pose a risk to the subjects if they were instructed to perform the 
same length and frequency of ACT.   
Another limitation of our study design as an at-home program is that it requires a 
certain level of motivation from the patients to fully participate. Yet, we believe this is an 
acceptable limitation because outside of the study, those who would implement the 
regimen into their lifestyle would need to have some level of motivation as well. 
Regardless, the results of this study are not as generalizable to those who either do not 
desire or do not have the ability to exercise regularly.  
4.2 Clinical and Public Health Significance  
The addition of CF treatments to other personal responsibilities for adults with CF 
can be burdensome. Therefore, the treatments that patients perform should be beneficial 
to their health to maximize their use of time. Both exercise and ACT are recommended 
therapies, but a program that combines both may provide even greater effects on lung 
function. Preservation of lung function in patients with CF is extremely important in 
preventing health decline and further sequelae of the disease. The proposed study will 
start to examine this relationship between the timing and integration of exercise and ACT 
on lung function longitudinally.  
If an integrated exercise and ACT program is found to improve lung function, 
then CF providers will have a specific regimen to provide to their patients. Importantly, 
the regimen still allows for personal adjustments and preferences, so it can be 
individually tailored for each subject. Hopefully, the integrated program will also 
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increase patient adherence to exercise and ACT both as a result of improved lung 
function as well as the feasibility of implementation into daily life. In addition to 
improved lung function, if the intervention decreases exacerbation frequency, this will 
also drastically affect the daily lives of patients. Fewer exacerbations would better 
preserve lung function and lessen the need for antibiotics and hospitalizations. These 
results could ultimately lead to an improved quality of life for patients with CF.  
If the proposed integrated program does not have a significant effect on lung 
function in the study, then perhaps the order and timing of ACT and exercise are not as 
important as long as they are completed. If this is the case, ACT and exercise should 
continue to be recommended to patients, but it could be argued that the combination does 
not maximize benefits. The results of the secondary outcomes must also be considered in 
this situation because it could be possible that the intervention does not significantly 
affect lung function, but it may decrease exacerbations or improve quality of life, both of 
which are likely valued by patients with CF. Either way, the results of this study will 
provide greater insight into the best methods for patients to perform exercise and ACT. 
Additionally, the details of the intervention (time and frequency of exercising, monitoring 
of exercise, ACT session length and frequency, etc.) could be adjusted for future studies 
to determine the most effective regimen to improve lung function.  
In conclusion, the integration of ACT and exercise in patients with CF has an 
encouraging potential to improve lung function over time. The proposed study will allow 
CF providers to make recommendations for ACT and exercise to their patients based on 
long-term results of lung function and exacerbation frequency. Overall, this study has the 





Appendix A. Sample Consent Form  
Written with the 200 FR.1 HIC Consent Template 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR. 1 (2016-2) 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE NEW HAVEN 
HOSPITAL 
Study Title: A Structured Airway Clearance and Exercise Program to Improve Clinical 
Outcomes in Cystic Fibrosis  
Principal Investigator: Rachel Rose, PA-SII 
Co-Principal Investigator: Clemente Britto-Leon, MD 
 
Invitation to Participate and Description of Project  
We are inviting you to participate in a research study designed to evaluate the 
effectiveness of an integrated exercise and airway clearance therapy on lung function in 
adults with cystic fibrosis. You have been asked to participate because you have been 
diagnosed with cystic fibrosis and you are older than 18 years. Approximately 77 people 
will participate in this study.  
Before you decide if you want to partake in this research study, it is important that you 
are aware of the risks and benefits in order to make an informed decision. This consent 
form will present you with information regarding the study, and this will be discussed 
with a research team member. The details to be discussed include the purpose, procedures 
to be performed, possible risks and benefits, and possible alternative treatments. Upon 
reading this form, you will be asked to sign this form if you wish to participate.  
 
Description of Procedures  
If you choose to participate in this study, you will be randomly assigned to either the 
intervention group or the control group. In the intervention group, you will be asked to 
perform an integrated program of exercise and airway clearance therapy (ACT). This will 
entail performing 30 minutes of exercise prior to an ACT session three times per week. 
You may choose your type of exercise from a list of accepted forms, and you will be 
asked to measure your heart rate before, once during, and after the 30 minutes of 
exercise. You will receive instructions on how to measure your heart rate prior to starting 
the study.  
In the control group, you will be asked to perform 30 minutes of exercise from a list of 
accepted forms three times weekly. The exercise sessions must be separated by any ACT 
sessions by at least 2 hours. You will be asked to measure your heart rate before, once 
during, and after exercise, and you will receive instruction on how to measure your heart 
rate prior to starting the study.  
In both groups, you will be asked to continue your CF appointments at the adult CF clinic 
every three months where you will perform spirometry and fill out a questionnaire on 
quality of life. You will also receive a phone call on the months that you do not have an 
appointment to discuss any questions. Additionally, you will be asked to fill out a daily 
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journal to record activity levels. The journal will include type of exercise performed, type 
of ACT performed, length of ACT performed, any side effects noticed, and heart rate 
measurements. This study will last for a time period of one year.  
During the study, you may continue any other treatments you are receiving. You will not 
be standardized to a specific amount or method of ACT, and you should continue this as 
prescribed by your provider.  
As required by U.S. Law, a description of this study can be found on 
http://www.ClinicalTrials.gov. This is a database that is used for people to see what 
studies are being done and what studies have been completed. The website will not 
include any information that can identify you, and will, at most, show a summary of the 
results. You may search this website at any time.  
You will be told of any significant new findings that are developed during the course of 
your participation in this study that may affect your willingness to continue to participate. 
If research results are published, your name and other personal information will not be 
given.  
 
Risks and Inconveniences  
Both exercise and airway clearance therapy have been studied in many clinical trials, and 
they are recommended in the treatment of cystic fibrosis. The incidence of side effects in 
previous similar studies is rare, but they can occur.  
Exercising carries certain risks or bodily harm that includes: physical injury (strain, 
fracture, etc.), acute dyspnea and cough, hypoglycemia, worsening of arthritis, cardiac 
arrhythmias, pneumothorax, and loss of consciousness. Some people may also experience 
soreness or stiffness after exercise. We will minimize these risks by encouraging you to 
wear proper clothing and shoes for exercise. We also ask that you discontinue exercising 
if you experience any side effects and either call the number listed on your daily journal 
or record the event in your daily journal.  
Other risks from participating in the study include the breach of confidentiality about 
your health status and participation in the study. This is very unlikely to occur, as all 
study investigators are trained and certified in research privacy.  
In the case of injury during the study, Yale School of Medicine and Yale New Haven 
Hospital will not cover the costs of a research-related injury. If you are injured, treatment 
will be provided, but you or your insurance carrier will be expected to pay for the 
treatment costs. There is no additional monetary compensation if you are injured.  
 
Benefits  
The results from this study may provide greater insight into the most effective integration 
of both exercise and ACT as CF therapies. The potential benefits of this study include 
improved lung function, decreased exacerbations, and improved health-related quality of 
life.  
 
Economic Considerations  
There are no costs associated with your participation in the study. 
 
Treatment Alternatives/Alternatives  
If you decide not to participate in this study, the alternative treatment is to continue your 




Confidentiality and Privacy  
Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or 
State law. Examples of information that we are legally required to disclose include abuse 
of a child or elderly person, or certain reportable diseases. Data will be stored on a 
HIPAA compliant and encrypted device that is password protected. When the results of 
the research are published or discussed in conferences, no information will be included 
that would reveal your identity unless your specific permission for this activity is 
obtained.  
We understand that information about your health is personal, and we are committed to 
protecting the privacy of that information. If you decide to be in this study, the researcher 
will get information that identifies your personal health information. This may include 
information that might directly identify you, such as his or her name and address, 
telephone number, and email address, or mobile phone number. This information will be 
de-identified at the earliest reasonable time after we receive it, meaning we will replace 
your identifying information with a code that does not directly identify you. The principal 
investigator will keep a link that identifies you and your coded information, and this link 
will be kept secure and available only to the principal investigator or selected members of 
the research team. Any information that can identify you will remain confidential. The 
research team will only give this coded information to others to carry out this research 
study. The link to your personal information will be kept for 5 years, after which time the 
link will be destroyed and the data will become anonymous. The data will be kept in this 
anonymous form indefinitely.  
 
The information about your health that will be collected in this study includes:  
• Results of lung function testing and health-related quality of life survey answers  
• Records about the monthly phone calls made as part of this research  
• Records in medical chart regarding exacerbations during study period  
 
Information about your health which might identify you may be used by or given to:  
• The U.S. Department of Health and Human Services (DHHS) agencies  
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Yale Human Investigation Committee (the committee that 
reviews, approves, and monitors research on human subjects), who are 
responsible for ensuring research compliance. These individuals are required to 
keep all information confidential.  
 
By signing this form, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose for the uses and disclosures you are 
authorizing is to ensure that the information relating to this research is available to all 
parties who may need it for research purposes.  
All health care providers subject to HIPAA (Health Insurance Portability and 
Accountability Act) are required to protect the privacy of your information. The research 
staff at the Yale School of Medicine are required to comply with HIPAA and to ensure 
the confidentiality of your child’s information.  
 
 61 
If you choose to participate in this study, the investigators will check your electronic 
medical record at Yale (EPIC) to make sure you qualify. Any access to your electronic 
medical record will be done consistent with HIPAA regulations.  
Some of the individuals or agencies listed above may not be subject to HIPAA and 
therefore may not be required to provide the same type of confidentiality protection. They 
could use or disclose your information in ways not mentioned in this form. However, to 
better protect your health information, agreements are in place with these individuals 
and/or companies that require that they keep your information confidential.  
You have the right to review and copy your health information in your medical record in 
accordance with institutional medical records policies. This authorization to use and 
disclose your health information collected during your participation in this study will 
never expire.  
 
Voluntary Participation  
You are free to choose not to participate in this study. Your health care outside the study, 
the payment for your health care, and your health care benefits will not be affected if you 
do not agree to participate. However, you will not be able to enroll in this research study 
and will not receive study procedures as a study participant if you do not allow use of 
your information as part of this study.  
 
Withdrawing From the Study  
If you do become a subject, you are free to stop and withdraw from this study at any time 
during its course. To withdraw from the study, you can call a member of the research 
team at any time and tell them that you no longer want to take part.  
The researchers may withdraw you from participating in the research if necessary. This 
includes, but is not limited to, non-compliance (i.e. not attending appointments) or in the 
cases of serious side effects.  
If you choose not to participate or if you withdraw it will not harm your relationship with 
your own doctors or with the Yale School of Medicine and Yale New-Haven Hospital.  
When you withdraw your permission, no new health information identifying you will be 
gathered after that date. Information that has already been gathered may still be used and 
given to others until the end of the research study, as necessary to insure the integrity of 
the study and/or study oversight.  
 
You do not give up any of your legal rights by signing this form.  
 
Questions  
As this form contains detailed information and technical terms, please feel free to ask any 
questions regarding the study. You may take as much time as you need to consider 
joining this study before you make a final decision.  
 
Authorization  
I have read (or someone has read to me) this form and have decided to participate in the 
project described above. Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction. My 
signature also indicates that I have received a copy of this consent form.  
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___________________________________________ ___________________  
Signature of Principal Investigator       Date  
or  
___________________________________________ ___________________  
Signature of Person Obtaining Consent                          Date  
 
If you have further questions about this project, or if you have a research-related problem, 
you may contact the Principal Investigator, Rachel Rose PA-SII (***) ***- **** or the 
Co-Principal Investigator, Clemente Britto-Leon, MD (***) *** -****.   
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 




Appendix B. Sample Recruitment Flyer  
 
Volunteers Needed for a Cystic 
Fibrosis Research Study 
 
We are looking for participants in a study to determine if 
combining exercise with airway clearance therapy improves lung 
function, decreases exacerbations, and improves quality of life in 
people with cystic fibrosis.  
 
You May Be Eligible If:  
• You have been diagnosed with cystic fibrosis  
• You are at least 18 years of age  
• You are able to participate in exercise  
• You are currently performing some form of airway clearance therapy 
 
What Will You Have to Do?  
• Complete 30 minutes of exercise three times per week  
• Fill out a daily journal  
o Record the amount of time and type of exercise and airway 
clearance therapy performed  
o Record your heart rate before, during, and after exercise  
• Continue attending quarterly CF appointments for spirometry and to 
fill out a quality of life questionnaire  
 
 
If you are interested in participating, or if you have any 
questions, please contact:  
 
Rachel Rose, Principal Investigator: (***)***-**** or at 
********@yale.edu 
 
You may also discuss this with your CF provider at your 

























Appendix D. List of Exercise Options  
 
You may choose any form of exercise listed below to complete your 30 minutes of 
exercise 3 times per week: 
 
• Running  
• Fast Walking 
• Biking  
• Hiking  
• Aerobics Class  
• Jumping (Jump Rope, Trampoline, etc.)  
• Kickboxing  
• Boxing  
• Swimming  
• Circuit Training  
• Dancing  
• Rowing  
• High-intensity Interval Training  
• Elliptical  
• Stair Machine  
• Cross-country Skiing  
• Basketball  
• Soccer  
 
If you have any other preferred exercises, please contact our research team at 




Appendix E: Sample Exercise and ACT Daily Log   
 
Directions: Please fill out one row of the table below every day. Under “Exercise 
Minutes” and “ACT Minutes,” record the number of minutes spent on each therapy, and 
under “Exercise Activity” and “ACT Method,” write what type of exercise you 
completed and which type of ACT you used. On days you do not exercise or do ACT, 
record 0 minutes and leave the activity or method box blank. The “Side Effects” column 
is for you to record any side effects you notice while completing the exercise and ACT. If 
you do not experience any side effects, leave the box blank.  
 
On the three days per week that you exercise, record your heart rate before exercise (#1), 
once in the middle of exercise (around 15 minutes, #2), and after completing exercise 
(#3). Please calculate your heart rate as demonstrated by our research team at your first 
appointment. Also, use the target heart rate you have been provided with as a goal—If 
your heart rate is lower than the target in the middle of exercise, then increase the 
intensity of exercise as tolerated.  
 
Please bring this log with you to all of your appointments at your CF clinic over the next 




















         
         
         
         
         
         




Appendix F. Calculations for Target Heart Rate  
 
1. Maximum heart rate will be calculated according to CDC guidelines1: 
220 – Age (In Years) 
2. Target heart rate will be in the range of 70-85% of maximum heart rate:  
.70 (Maximum HR) to 0.85 (Maximum HR) 
 
Example: For a person 25 years of age… 
Maximum Heart Rate: 220 - 25 = 195 
0.70 (195) = 136.5  
0.85 (195) = 165.75 





Appendix G. Sample Size Calculation 
 
Sample size calculation based on: 
 Alpha (α, level of significance) = 0.050 
 B (β, type II error) = 0.10, Power of 90%  
μ1 = 5.76%  ± 3.70 
μ2 = -4.42% ± 14.70 
n = 25 per group 
Adding an additional 10 subjects to each arm plus a 10% dropout rate results in a total 
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